Lenvatinib
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Hepatocellular
Conditions
Carcinoma, Hepatocellular, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms
Trial Timeline
May 14, 2019 → Jan 28, 2022
NCT ID
NCT04008082About Lenvatinib
Lenvatinib is a pre-clinical stage product being developed by Eisai for Carcinoma, Hepatocellular. The current trial status is completed. This product is registered under clinical trial identifier NCT04008082. Target conditions include Carcinoma, Hepatocellular, Carcinoma, Neoplasms, Glandular and Epithelial.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533361 | Pre-clinical | Completed |
| NCT02211222 | Pre-clinical | Completed |
| NCT05901194 | Phase 1/2 | Active |
| NCT06138769 | Phase 2 | Active |
| NCT05171335 | Phase 2 | Recruiting |
| NCT05103904 | Phase 2 | Recruiting |
| NCT04321954 | Phase 2 | Active |
| NCT04297254 | Approved | Completed |
| NCT04447755 | Phase 2 | Completed |
| NCT04008082 | Pre-clinical | Completed |
| NCT03506048 | Phase 2 | Terminated |
| NCT03009292 | Phase 1 | Completed |
| NCT03663114 | Pre-clinical | Completed |
| NCT02846766 | Phase 2 | Withdrawn |
| NCT03433703 | Phase 2 | Terminated |
| NCT03573960 | Approved | Completed |
| NCT03168074 | Phase 2 | UNKNOWN |
| NCT02953743 | Phase 1 | Completed |
| NCT02780310 | Phase 2 | Active |
| NCT02579616 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Hepatocellular